Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer (PROFILER)
It is a non-randomized, multicentric, cohort study, combined with a biological sample collection, a retrospective clinical data collection and with a genetic and immunologic biomarkers study.
The ProfiLER program aims to implement a personalized cancer medicine approach in the Centre Leon Berard by proposing to establish the genetic and immunologic profile of the tumor for patients with an advanced malignant tumor, in order to define a map of genetic (for the pre-identified target genes) and immunologic profiles for all the studied types of cancer. This study will also allow adapting the therapeutic management of these patients, if needed, by giving them targeted therapies or immunotherapies (commercialized on in ongoing clinical trials), based on the recommendations of the multidisciplinary molecular board.
The genetic and immunologic profile of the tumor will be determined from archival or fresh collected (biopsy of a reachable lesion) tumor sample and from a blood sample. The correlation between genetic profiles of the tumor, patients immunity status and retrospective clinical data (progression, tumor response, etc.) collected from the patient medical records will probably allow us to identify biomarkers with a potential predictive value and to determine if some genetic disorders are linked to immunity status alterations.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer|
- Establish a map of genetic profiles (for the pre-identified target genes) for all types of advanced malignant tumors. [ Time Frame: 3 years after first patient enrollment ] [ Designated as safety issue: No ]Description of the incidence rates of each detected genetic disorder among the pre-identified target genes in the global cohort and for each histological type.
- Establish a map of immunologic profiles for all types of advanced malignant tumors. [ Time Frame: 3 years after first patient enrollment ] [ Designated as safety issue: No ]Description of the incidence rates of each detected immunologic disorder in the global cohort and for each histological type.
- Determine for each histological type of tumor, characteristic profiles of genetic and/or immunologic disorders and disorders that might be common to several histological types. [ Time Frame: 3 years after first patient enrollment ] [ Designated as safety issue: No ]Comparison of the genetic and immunologic profiles between patients with the same tumor type or between tumors of different types.
- Identify genetic and/or immunologic biomarkers (or molecular profiles) with a potential predictive value on response to treatments. [ Time Frame: 3 years after first patient enrollment ] [ Designated as safety issue: No ]Tumor response (determined by the investigator and/or the radiologist) assessed after each treatment received by the patient during his/her whole participation to the study (if data are available in the medical record).
- Identify biomarkers (constitutional or somatic alterations in tumor cells) that might be correlated with systemic or local alterations of the immunity status observed in some patients with advanced cancers [ Time Frame: 3 years after first patient enrollment ] [ Designated as safety issue: No ]lymphopenia, over-representation of Treg, dendritic cells alterations,
- Assess the changes of genetic and/or immunologic profiles in case of progressive disease [ Time Frame: 3 years after first patient enrollment ] [ Designated as safety issue: No ]
|Study Start Date:||February 2013|
|Estimated Study Completion Date:||March 2016|
|Estimated Primary Completion Date:||March 2016 (Final data collection date for primary outcome measure)|
|Experimental: Blood and tumor samples||
Genetic: Blood and tumor samples
Genetic: Establishment of the genetic and immunologic profile
Whole blood sampling :
Collection of the available archival tumor sample (frozen or FFPE) if the patient has not progressed since the last treatment.
•If there's no available sample or in case of progressive disease, the investigator will prescribe a biopsy of a reachable lesion (2 samples must be collected: a frozen one and a FFPE one).
With the established profile, recommendations will be given by a multidisciplinary molecular board.
Determination of the tumor profile and review in multidisciplinary molecular board:
The genetic and immunologic profile will be performed from the available tumor sample and from a blood sample.
- Research of mutations/insertions/deletions for an array of predefined genes in tumor deoxyribonucleic acid by high-throughput sequencing
- Analysis of copy number variations of genes on tumor deoxyribonucleic acid by microarray-based comparative genomic hybridization
- Analysis of rearrangements involving the gene Anaplastic Lymphoma Kinase that can't be detected by Next Generation Sequencing or array Comparative Genomic Hybridization (balanced translocations) by means of fluorescent hybridization probes on tumor samples Immunologic profile: analysis of the expression of relevant immunologic markers
Retrospective clinical data collection:
Patients' clinical data will be collected retrospectively from the patient medical record. This study is not a treatment evaluation. Patients' follow-up and treatment will be performed according to the center local practices or to the specificities of a clinical trial in which the patient would have been enrolled, depending on the recommendations given by the multidisciplinary molecular board, with the review of the tumor genetic profile.
|Contact: Christelle SEIGNE, PhD||+33 4 26 55 68 email@example.com|
|Contact: Mathilde BERNARDIN||+33 4 26 55 68 firstname.lastname@example.org|
|Centre Léon Bérard||Not yet recruiting|
|Lyon, France, 69008|
|Sub-Investigator: Thomas BACHELOT, MD|
|Sub-Investigator: Amine BELHABRI, MD|
|Sub-Investigator: Christophe BERGERON, MD|
|Sub-Investigator: Pierre BIRON, MD|
|Sub-Investigator: Helen BOYLE, MD|
|Sub-Investigator: Philippe CASSIER, MD|
|Sub-Investigator: Patrick COMBEMALE, MD|
|Sub-Investigator: Françoise DESSEIGNE, MD|
|Sub-Investigator: Cécile FAURE-CONTER, MD|
|Sub-Investigator: Jérome FAYETTE, MD|
|Sub-Investigator: Aude FLECHON, MD|
|Sub-Investigator: Christelle DE LA FOUCHARDIERE, MD|
|Sub-Investigator: Didier FRAPPAZ, MD|
|Sub-Investigator: Hervé GHESQUIERES, MD|
|Sub-Investigator: Jean-Paul GUASTALLA, MD|
|Sub-Investigator: Pierre GUIBERT, MD|
|Sub-Investigator: Pierre-Etienne HEUDEL, MD|
|Sub-Investigator: Aurélien MARABELLE, MD|
|Sub-Investigator: Sylvie NEGRIER, MD|
|Sub-Investigator: Eve-Marie NEIDHARDT, MD|
|Sub-Investigator: Emmanuelle NICOLAS-VIRELIZIER, MD|
|Sub-Investigator: Maurice PEROL, MD|
|Sub-Investigator: Isabelle RAY-COQUARD, MD|
|Sub-Investigator: Paul REBATTU, MD|
|Sub-Investigator: Catherine SEBBAN, MD|
|Sub-Investigator: Olivier TREDAN, MD|
|Hôpital Edouard Herriot||Not yet recruiting|
|Lyon, France, 69003|
|Principal Investigator: Julien FORESTIER, MD|
|Sub-Investigator: Catherine LOMBARD BOHAS, MD|
|Sub-Investigator: Thomas WALTER, MD|
|Centre Hospitalier Lyon Sud||Not yet recruiting|
|Pierre-Bénite Cedex, France, 69495|
|Principal Investigator: Benoît YOU, MD|
|Sub-Investigator: Cécile FOURNEL-FEDERICO, MD|
|Sub-Investigator: Gilles FREYER, MD|
|Sub-Investigator: Sophie TARTAS, MD|
|Sub-Investigator: Véronique TRILLET-LENOIR, MD|
|Principal Investigator:||Jean-Yves BLAY, MD PhD||Centre Léon Bérard|